Activin signaling inhibitor: from clinical outcomes to physiologic understanding

29 August 2026 (15:42 - 15:50)

Organised by:

About the speaker

Doctor Thomas Cascino

University of Michigan, Ann Arbor (United States of America)

4 More presentations in this session

Presentation thumbnail

Effects of activin signaling inhibitor on afterload, right ventricular function, and structure: a 3-prong view

Doctor A. Vaidya (Temple, US)

Presentation thumbnail

Disentangling the central, peripheral, and haematological mechanisms of benefit of activin signaling inhibitor on exercise performance in pulmonary arterial hypertension

Assistant Professor Y. Reddy (Rochester, US)

Presentation thumbnail

Haemodynamic parameters as part of risk assessment in pulmonary arterial hypertension: does cardiac output matter?

Doctor A. Boucly (Le Kremlin Bicetre, FR)

Presentation thumbnail

Contextualising outcomes behind activin signaling inhibitor in pulmonary arterial hypertension - discussion and Q&A

Access the full session

Session thumbnail

Contextualising outcomes behind activin signaling inhibitor in pulmonary arterial hypertension

The Event

Event poster

ESC Congress 2026

29 August 2026 15:42 CET

You may be interested in

Congress Presentation

Activin signalling inhibitors

30 August 2025

Congress Presentation

Inhibin Beta-A is a novel gene involved in the development of pulmonary arterial hypertension through inhibiting BMPRII-signaling in endothelial cells

3 September 2019

Congress Session

State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?

14 March 2025

Congress Presentation

Tocilizumab is associated with a lower incidence of major adverse cardiovascular events in Giant Cell Arteritis

29 August 2026

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources